Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label denosumab study in giant cell-rich bone tumors
NL-OMON47771Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of denosumab in Giant Cell Tumor of Bone (GCTB), aneurysmal bone cyst (ABC), central giant cell granuloma (CGCG) and 3 more (2 cohorts), sponsored by Leiden University Medical Center. Primary endpoints: Avoidance of surgery during study, Reduction in surgical morbidity and 2 more. Started Jun 2018; status: completed.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)aneurysmal bone cyst (ABC)central giant cell granuloma (CGCG)osteoblastomafibroblastoma
Beyond the preview
Go deeper on NL-OMON47771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47771.